Orexin A
Also known as: Hypocretin-1, OXA, Orexin-A, HCRT1, Prepro-orexin-derived peptide A
Hypothalamic neuropeptide / excitatory peptide
What it is
Orexin A is a wakefulness-promoting brain peptide studied as a biomarker for narcolepsy and neurodegenerative diseases, and for its potential role in regulating sleep, appetite, and metabolism. Researchers are investigating it as a diagnostic tool and therapeutic target. Not FDA-approved as a therapeutic; drugs that block its receptor are FDA-approved for insomnia.
The scientific side
Orexin A is an excitatory neuropeptide produced primarily in the lateral hypothalamus. It acts on two G-protein-coupled receptors, OX1R and OX2R, which are expressed in the central nervous system and various peripheral tissues including the gastrointestinal tract, kidneys, adrenal glands, pancreas, and placenta. Through OX1R and OX2R signaling, Orexin A participates in the regulation of sleep-wake cycles, arousal, feeding behavior, energy homeostasis, autonomic (sympathetic) tone, reward-seeking, stress responses, and pain modulation. It modulates downstream intracellular pathways including mTOR/p70S6K1, MAPK/ERK, NF-κB, JAK2/STAT3, and PI3K/AKT/mTOR. In peripheral tissues, it exerts anti-inflammatory effects by reducing pro-inflammatory cytokine production and inhibiting NF-κB activation. Its roles in gut-brain signaling, neurodegeneration, and immune modulation are areas of active investigation.
Class: Hypothalamic neuropeptide / excitatory peptide
Legal & regulatory status
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
What it's studied for
- Narcolepsy diagnosis (CSF biomarker) Human observational
- CSF Orexin-A concentrations were lower in narcolepsy type 1 patients (median <35 pg/mL) than in controls (98 pg/mL). LC-MS/MS values were approximately 5× lower than those obtained by radioimmunoassay (RIA), indicating assay-dependent variability. PMID 33539807 Lindström et al., Clinical Biochemistry (2021)
- CSF hypocretin-1 (orexin-A) levels evaluated in childhood narcolepsy and various neurologic disorders. PMID 15623725 Arii et al., Neurology (2004)
- Sleep-wake regulation and sleep disorder biomarker Human observational
- Serum OXA levels were significantly higher in pregnant women with poor sleep quality vs. those without (0.33 vs. 0.27 arbitrary units, P<0.001). OXA levels were elevated in second and third trimesters vs. first trimester. PMID 36368074 Qin et al., Sleep Medicine (2023)
- Bibliometric analysis identified 'sleep' as the second most frequent keyword (824 publications) in the orexin literature, underscoring its centrality to sleep research. PMID 39470537 Sun et al., Medicine (2024)
- Sympathetic vascular tone modulation (intranasal administration in healthy humans) Human RCT
- In a double-blind crossover RCT in 10 lean healthy males, intranasal orexin A (500 nmol) significantly increased resting muscle sympathetic nerve activity (MSNA) compared to placebo (burst rate: +5.8 ± 0.8 vs. +2.1 ± 0.6 bursts/min, P=0.007). Blood pressure, heart rate, and baroreflex sensitivity were not altered. PMID 35044844 Meusel et al., Journal of Neurophysiology (2022)
- Metabolic regulation and obesity (dietary intervention biomarker) Human RCT
- In a 12-month RCT (n=30 adults with obesity), 16:8 time-restricted eating showed the most consistent longitudinal increase in Orexin-A levels. Increases in Orexin-A were associated with improved metabolic flexibility and reduced inflammation across all dietary groups. PMID 41599851 Monda et al., Nutrients (2026)
- Plasma Orexin-A was lower in obese adults (85.34 ± 42.85 ng/L) than overweight (97.38 ± 36.72 ng/L) and normal-weight controls (106.56 ± 52.09 ng/L, P=0.03). Plasma Orexin-A correlated with total, moderate, and walking physical activity. PMID 27038345 Hao et al., Eating and Weight Disorders (2017)
- Neurocognitive and neurodegenerative disorder biomarker (Alzheimer's disease, frontotemporal dementia, Parkinson's disease, Lewy body disease) Human observational
- CSF Orexin-A levels differed significantly across neurocognitive disorders: highest in iNPH (263.31 ± 56.89 pg/mL), elevated in NFPA and msAD vs. controls (145.18 ± 27.01 pg/mL); mAD had the lowest levels among patient groups. PMID 40198471 Lozano-Tovar et al., Neurological Sciences (2025)
- Meta-analysis of 18 studies (244 PD patients): CSF Orexin-A concentrations were lower in PD patients than controls (mean difference −59.21, 95% CI: −89.10 to −29.32), but within normal range. PMID 38781804 Suresh et al., Clinical Neurology and Neurosurgery (2024)
- Meta-analysis (179 LBD patients, 253 controls): Orexin-A CSF levels in LBD were approximately equal to healthy elderly individuals but lower than AD patients (SMD: −0.35) and higher than FTLD patients (SMD: 0.61). PMID 34867809 Gan et al., Frontiers in Endocrinology (2021)
- CSF Orexin-A was significantly elevated in bvFTD patients vs. non-demented controls (p<0.001) and correlated with MMSE scores, compulsive behavior, and CSF neurodegeneration markers (tau, Aβ1-42). PMID 33904007 Roveta et al., Neurological Sciences (2022)
- Orexin-A expression was reduced in AD mice after acute sleep deprivation; molecular dynamics simulations suggested orexin-A binds Aβ with high affinity and inhibits its aggregation. PMID 41335394 Singh et al., Molecular Neurobiology (2025)
- Schizophrenia and antipsychotic treatment response biomarker Human observational
- Clozapine-responsive patients (n=100) had higher Orexin-A levels than clozapine-resistant (n=62) and APD-free patients. Orexin-A was the only factor significantly associated with treatment response. Orexin-A positively correlated with verbal memory, visual learning, and working memory. PMID 38279671 Chen et al., Journal of Psychopharmacology (2024)
- APD-treated patients had higher Orexin-A than drug-free patients; aripiprazole-treated had higher levels than clozapine-treated. APD treatment was independently associated with Orexin-A upregulation after controlling for metabolic syndrome. PMID 35396156 Chen et al., Journal of the Formosan Medical Association (2022)
- Orexin-A levels were highest in the less-obesogenic antipsychotic group, followed by the clozapine group and controls. Higher Orexin-A was independently associated with lower risk of metabolic syndrome (adjusted OR=0.04 for 2nd and 3rd tertiles vs. 1st). PMID 30204875 Chen et al., International Journal of Neuropsychopharmacology (2019)
- Parkinson's disease non-motor symptom association (plasma biomarker) Human observational
- Plasma Orexin-A was significantly higher in early- and medium-stage PD vs. controls, but decreased in advanced-stage PD. Orexin-A correlated with sleep disorders, anxiety, cognitive dysfunction, and renal dysfunction non-motor symptoms. PMID 33161104 Huang et al., Neuroscience Letters (2021)
- Neuroprotection in cerebral ischemia/reperfusion injury (preclinical) Animal studies only
- OXA treatment in MCAO/R rat model improved neurological deficit scores, reduced infarct volume, inhibited astrocytic inflammation via NF-κB and MAPK pathways, and suppressed apoptosis. PMID 34358627 Xu et al., Biochimica et Biophysica Acta (2021)
- OXA exerted neuroprotective effects in MCAO rat and OGD/R cell models by suppressing over-activated autophagy via OX1R-mediated MAPK/ERK/mTOR pathway. PMID 33212156 Xu et al., Cellular Signalling (2021)
- Acute ischemic stroke prognosis biomarker Human observational
- Serum Orexin-A was higher in mild-to-moderate AIS patients with short-term neurological improvement (31.78 vs. 16.24 pg/mL, P=0.038) and was positively associated with neurological improvement after multivariate adjustment. PMID 36573700 Hu et al., Brain and Behavior (2023)
- Cognition enhancement / cognitive impairment rescue (preclinical, intranasal) Animal studies only
- Nasal administration of Orexin A partially rescued MK-801 (dizocilpine)-induced cognitive impairment in visual discrimination task in female C57BL/6J mice but not males. PMID 37172740 Durairaja et al., Behavioural Brain Research (2023)
- Orexin A transgenic rats showed improved memory performance under hypoxic conditions (5000–7000 m simulated altitude) with upregulated BDNF/TrkB and PI3K/AKT/mTOR signaling and attenuated microglial activation. PMID 41072850 Zhu et al., Behavioural Brain Research (2026)
- Glioblastoma proliferation inhibition (preclinical) Mixed
- Orexin-A inhibited GBM proliferation by inducing ferroptosis via increased iron levels and GPX4 depletion, with regulation of TFRC, FTH1, and GPX4 via NFE2L2 targeting. Evidence from multi-omics, flow cytometry, and animal models. PMID 38685674 Huan et al., Journal of Cellular and Molecular Medicine (2024)
- Colon cancer immune modulation (preclinical) Mixed
- Orexin A suppressed exosomal PD-L1 expression in colon cancer cells and promoted T-cell activity by inhibiting JAK2/STAT3 signaling. Orthotopic transplanted colon cancer grew slower in the Orexin A-treated group with lower PD-L1 and higher immune infiltration. PMID 34097168 Wen et al., Digestive Diseases and Sciences (2022)
- Cortisol secretion regulation in adrenocortical cells (preclinical) In vitro only
- Orexin-A/OX1R activated mTOR/p70S6K1 pathway, inhibiting autophagy and increasing cortisol secretion in H295R and Y-1 adrenocortical cells via upregulation of 3β-hydroxysteroid dehydrogenase/isomerase. PMID 37572990 Guo et al., Biochimica et Biophysica Acta (2024)
- Osteoarthritis / chondrocyte senescence protection (preclinical) In vitro only
- Orexin-A ameliorated IL-1β-induced cellular senescence in TC-28a2 chondrocytes by rescuing telomerase activity, reducing Acetyl-p53 and p21, and mitigating SIRT3 reduction. SIRT3 silencing abolished protective effects. PMID 38829778 Shen et al., Aging (2024)
- Polycystic kidney disease (expression and renal function correlation) Human observational
- Serum Orexin-A levels were significantly higher in ADPKD patients than healthy controls (477.07 ± 69.42 vs. 321.49 ± 78.01 pg/mL, P<0.001). Orexin-A inversely correlated with blood pressure and directly correlated with eGFR in PKD patients. PMID 38892431 Nigro et al., International Journal of Molecular Sciences (2024)
- Diabetic retinopathy staging biomarker Human observational
- Mean serum Orexin-A levels were significantly lower in all type 2 DM subgroups vs. healthy controls (P<0.001), but did not differ significantly across diabetic retinopathy progression stages. PMID 39009974 Alkan et al., Clinical & Experimental Optometry (2025)
- Substance use disorder (opioid, methamphetamine, heroin) biomarker Human observational
- Serum Orexin-A levels were significantly higher in male HUD patients undergoing MMT than in healthy controls (BMI-adjusted ANCOVA). PMID 29680730 Tsai & Huang, Psychiatry Research (2018)
- Recent methamphetamine abusers (use within 3 weeks) had significantly higher fasting serum Orexin-A levels than healthy controls. PMID 27137956 Chen et al., Psychiatry Research (2016)
- CSF Orexin-A levels were elevated in both pure-opioid and multi-drug abusers vs. controls in a postmortem study. PMID 32741526 Sadat-Shirazi et al., Neuropeptides (2020)
- Multiple sclerosis disease progression biomarker Human observational
- MS patients had significantly lower serum Orexin-A than healthy controls; SPMS patients had significantly lower Orexin-A than RRMS patients. Serum Orexin-A negatively correlated with 9-HP, T25-FW test scores, and progression index in RRMS. PMID 30645749 Gencer et al., Neurological Sciences (2019)
- ADHD neurobiological association Human observational
- Serum Orexin-A levels were significantly lower in drug-naive children with ADHD vs. healthy controls (P=0.001), and lowest in the inattentive subtype vs. hyperactive and combined subtypes (P=0.009). PMID 30617449 Baykal et al., Neurological Sciences (2019)
- Epileptic seizure differential diagnosis biomarker Human observational
- Mean blood Orexin-A was 11.08 ng/mL in epileptic seizures vs. 7.17 ng/mL in psychogenic non-epileptic seizures and 5.16 ng/mL in controls. ES group differed significantly from both other groups (P<0.001). PMID 32485288 Çikriklar et al., Neuroscience Letters (2020)
- Gut-brain axis modulation and gastrointestinal homeostasis Mixed
- Review summarizing Orexin-A's roles in gastrointestinal motility, secretion, short-term food intake, gastric acid secretion, and reduction of pro-inflammatory cytokines (TNF-α, IL-6, MCP-1) in colitis animal models. PMID 33068686 Mediavilla, Neurochemistry International (2020)
- Pain modulation Animal studies only
- Review demonstrating antinociceptive effects of orexins in multiple pain models (thermal, mechanical, chemical nociception; neuropathic pain; migraine; visceral and orofacial pain) at spinal and supraspinal levels, with possible endocannabinoid involvement in supraspinal analgesia. PMID 28360013 Razavi & Hosseinzadeh, Biomedicine & Pharmacotherapy (2017)
- Hepatoprotection against HBV X protein cytotoxicity (preclinical) In vitro only
- Orexin A mitigated HBx-induced oxidative stress (4-HNE, ROS, NOX-4), mitochondrial membrane potential loss, ATP reduction, pro-inflammatory cytokine production (IL-8, TNF-α, CXCL2), and cytotoxicity (LDH release) in hepatocytes, by suppressing JNK and NF-κB pathways. PMID 31106596 Wang et al., Artificial Cells, Nanomedicine, and Biotechnology (2019)
- Rheumatoid arthritis / synoviocyte anti-inflammatory effects (preclinical) In vitro only
- Orexin A reduced IL-1β, IL-6, IL-8, ROS, MMP-3, and MMP-13 in TNF-α-treated fibroblast-like synoviocytes (FLSs) by inhibiting NF-κB signaling. OX1R expression was decreased in RA-FLSs. PMID 30142537 Sun et al., Biomedicine & Pharmacotherapy (2018)
- Chronic cerebral hypoperfusion / vascular dementia neuroprotection (preclinical) Animal studies only
- Intranasal Orexin A (250 μg/kg) administered for 4 weeks in a VaD rat model ameliorated cognitive dysfunction, neuroinflammation, and BBB disruption by inhibiting the NEK7/NLRP3 pathway and promoting M1-to-M2 microglial transition. PMID 40691984 Chen et al., Experimental Neurology (2025)
- Reward / motivational behavior and food seeking (preclinical) Animal studies only
- Microinjection of Orexin-A into the VTA promoted palatable food seeking in rats, blocked by OX1R antagonist SB-334867. Orexin-A and μ-opioid receptor signaling modulated VTA dopamine neuron firing frequency. PMID 41762866 Luan et al., Biochemical and Biophysical Research Communications (2026)
- Review proposing that orexins primarily mediate motivated behaviors under high motivational relevance (physiological need states, threats, reward opportunities), integrating sleep/wake cycling under a 'motivational activation' framework. PMID 25254979 Mahler et al., Nature Neuroscience (2014)
- Peripheral tissue expression characterization Human observational
- Orexin-A immunoreactivity detected in sympathetic ganglia, myenteric plexuses, GI endocrine cells, pancreatic islet cells (majority co-positive with insulin), and placental syncytiotrophoblasts. mRNA for prepro-orexin found in kidney, adrenal gland, pancreas, placenta, stomach, ileum, colon. PMID 12890566 Nakabayashi et al., Molecular and Cellular Endocrinology (2003)
- IR-Orexin-A detected in human plasma (mean 1.94 ± 0.24 pmol/L in morning samples from 17 healthy subjects); no significant diurnal variation between morning and night samples. PMID 11179609 Arihara et al., Peptides (2001)
Protocol
No community protocol on record. In clinical studies, Orexin A was dosed at 500 nmol (intranasal, single administration) Intranasal (PMID 35044844).
All studies (44)
- PMID 27038345 Human RCT
Metabolic regulation and obesity (dietary intervention biomarker) - PMID 35044844 Human RCT
Sympathetic vascular tone modulation (intranasal administration in healthy humans) - PMID 41599851 Human RCT
Metabolic regulation and obesity (dietary intervention biomarker) - PMID 11179609 Human observational
Peripheral tissue expression characterization - PMID 12890566 Human observational
Peripheral tissue expression characterization - PMID 15623725 Human observational
Narcolepsy diagnosis (CSF biomarker) - PMID 27137956 Human observational
Substance use disorder (opioid, methamphetamine, heroin) biomarker - PMID 29680730 Human observational
Substance use disorder (opioid, methamphetamine, heroin) biomarker - PMID 30204875 Human observational
Schizophrenia and antipsychotic treatment response biomarker - PMID 30617449 Human observational
ADHD neurobiological association - PMID 30645749 Human observational
Multiple sclerosis disease progression biomarker - PMID 32485288 Human observational
Epileptic seizure differential diagnosis biomarker - PMID 32741526 Human observational
Substance use disorder (opioid, methamphetamine, heroin) biomarker - PMID 33161104 Human observational
Parkinson's disease non-motor symptom association (plasma biomarker) - PMID 33539807 Human observational
Narcolepsy diagnosis (CSF biomarker) - PMID 33904007 Human observational
Neurocognitive and neurodegenerative disorder biomarker (Alzheimer's disease, frontotemporal dementi - PMID 34867809 Human observational
Neurocognitive and neurodegenerative disorder biomarker (Alzheimer's disease, frontotemporal dementi - PMID 35396156 Human observational
Schizophrenia and antipsychotic treatment response biomarker - PMID 36368074 Human observational
Sleep-wake regulation and sleep disorder biomarker - PMID 36573700 Human observational
Acute ischemic stroke prognosis biomarker - PMID 38279671 Human observational
Schizophrenia and antipsychotic treatment response biomarker - PMID 38781804 Human observational
Neurocognitive and neurodegenerative disorder biomarker (Alzheimer's disease, frontotemporal dementi - PMID 38892431 Human observational
Polycystic kidney disease (expression and renal function correlation) - PMID 39009974 Human observational
Diabetic retinopathy staging biomarker - PMID 39470537 Human observational
Sleep-wake regulation and sleep disorder biomarker - PMID 40198471 Human observational
Neurocognitive and neurodegenerative disorder biomarker (Alzheimer's disease, frontotemporal dementi - PMID 41335394 Human observational
Neurocognitive and neurodegenerative disorder biomarker (Alzheimer's disease, frontotemporal dementi - PMID 33068686 Mixed
Gut-brain axis modulation and gastrointestinal homeostasis - PMID 34097168 Mixed
Colon cancer immune modulation (preclinical) - PMID 38685674 Mixed
Glioblastoma proliferation inhibition (preclinical) - PMID 25254979 Animal studies only
Reward / motivational behavior and food seeking (preclinical) - PMID 28360013 Animal studies only
Pain modulation - PMID 30142537 In vitro only
Rheumatoid arthritis / synoviocyte anti-inflammatory effects (preclinical) - PMID 31106596 In vitro only
Hepatoprotection against HBV X protein cytotoxicity (preclinical) - PMID 33080054
50 nmol/L and 100 nmol/L In vitro (cell culture treatment) (in_vitro) - PMID 33212156 Animal studies only
Neuroprotection in cerebral ischemia/reperfusion injury (preclinical) - PMID 34032542
Not an intervention study; observational measurement of serum Orexin-A levels Not applicable (serum measurement) (human) - PMID 34358627 Animal studies only
Neuroprotection in cerebral ischemia/reperfusion injury (preclinical) - PMID 37172740 Animal studies only
Cognition enhancement / cognitive impairment rescue (preclinical, intranasal) - PMID 37572990 In vitro only
Cortisol secretion regulation in adrenocortical cells (preclinical) - PMID 38829778 In vitro only
Osteoarthritis / chondrocyte senescence protection (preclinical) - PMID 40691984 Animal studies only
Chronic cerebral hypoperfusion / vascular dementia neuroprotection (preclinical) - PMID 41072850 Animal studies only
Cognition enhancement / cognitive impairment rescue (preclinical, intranasal) - PMID 41762866 Animal studies only
Reward / motivational behavior and food seeking (preclinical)